

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-191. (Canceled)

192. (Currently Amended) A method for modulating cell adhesion of cadherin-expressing cells comprising contacting the cells with a linear peptide that is 6-50 amino acid residues in length and that comprises ~~comprising one two~~ or more of the cell adhesion recognition sequence, His-Ala-Val, wherein said linear peptide modulates cell adhesion.

193. (Currently Amended) A method according to claim 192, wherein said linear peptide comprises a sequence selected from the group consisting of ~~HAV, HAVHAV (SEQ ID NO: 10), SHAHSVSHAVS (SEQ ID NO: 11), LRAHAVDING (SEQ ID NO: 21), LRAHAVDVNG (SEQ ID NO: 22), MRAHAVDING (SEQ ID NO: 23), HLGAAHAVDINGNQVET (SEQ ID NO: 24), FHLRAHAVDINGNQV (SEQ ID NO: 25), AHAVSE (SEQ ID NO: 27), AHAVDI (SEQ ID NO: 28), SHAHSV (SEQ ID NO: 29), LYSHAVSSNG (SEQ ID NO: 18), LFSHAVSSNG (SEQ ID NO: 19)~~ and derivatives of the foregoing sequences having one or more C-terminal, N-terminal and/or side chain modifications.

194. (Previously Presented) A method according to claim 192, wherein said linear peptide is linked to a targeting agent.

195. (Previously Presented) A method according to claim 192, wherein said linear peptide further comprises at least one separate cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

196. (Currently Amended) A method according to claim 192, wherein said ~~one~~ two or more of the cell adhesion recognition sequences, His-Ala-Val, are separated by a linker.

197. (Currently Amended) A method according to claim 195, wherein said separate cell adhesion recognition sequence comprises a sequence selected from the group consisting of: RGD, YIGSR (SEQ ID NO: 12), KYSFNYDGSE (SEQ ID NO: 13), IWKHKGRDVLKKDVRP (SEQ ID NO: 14), YAT, FAT, YAS₃, RAL₃, GVNPTAQSSGSLYGSQIYALCNQFYTPAATGLYVDQYLYHYCVVDPQ-E (SEQ ID NO: 15), QSSGSLYGSQ (SEQ ID NO: 16) and QYLYHYCVVD (SEQ ID NO: 17).

198. (Previously Presented) A method according to claim 192, wherein said linear peptide is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

199. (Previously Presented) A method according to claim 198, wherein said pharmaceutical composition further comprises at least one separate cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

200. (Currently Amended) A method according to claim 199, wherein said separate cell adhesion recognition sequence comprises a sequence selected from the group consisting of: RGD, YIGSR (SEQ ID NO: 12), KYSFNYDGSE (SEQ ID NO: 13), IWKHKGRDVLKKDVRP (SEQ ID NO: 14), YAT, FAT, YAS₃, RAL₃, GVNPTAQSSGSLYGSQIYALCNQFYTPAATGLYVDQYLYHYCVVDPQ-E (SEQ ID NO: 15), QSSGSLYGSQ (SEQ ID NO: 16) and QYLYHYCVVD (SEQ ID NO: 17).